miR-106 b expression in breast cancer tissues and mechanism of enhancing cisplatin sensitivity in breast cancer cells

doi:10.12092/j.issn.1009-2501.2019.05.010

Abstract

Abstract:

AIM: To explore miR-106 b expression in breast cancer tissues and mechanism of enhancing cisplatin sensitivity in breast cancer cells. METHODS: Fifty-eight cases of breast cancer patients diagnosed and treated in our hospital from October 2015 to May 2015 were randomly selected. Breast cancer tissue and paracancer tissue were taken. Cellular DNA was extracted from breast cancer tissues and adjacent tissues, and the expression level of miR-106 b was detected by real-time PCR. MCF-7 cell lines of breast cancer were purchased to construct the high-expression group promoting the expression of mir-106 b and the low-expression group inhibiting the expression of miR-106 b. After 48 h treatment with cisplatin at different concentrations, the inhibition of tumors in vitro and subcutaneous in nude mice was observed. Fluorescence quantitative PCR was used to detect the expression of PTEN/PI3K/AKT signaling pathway related genes.RESULTS:Real-time PCR showed that the relative expression of miR-106 b in breast cancer tissues was higher than that in adjacent tissues (P<0.05). At 20, 30 and 40 μmol/L concentrations, the cell inhibition rates of the control group and the high expression group were significantly higher than those of the low expression group, and the cell inhibition rate of the control group was significantly higher than that of the low expression group (P<0.05). At the concentrations of 20, 30 and 40 μmol/L, the fluorescence intensity at the corresponding concentrations in the control group and the high expression group was lower than that in the low expression group, and the high expression group was significantly lower than the control group (P<0.05). The relative expression of PTEN in the low expression group was significantly lower than that in the control group, while the relative expression of PTEN in the high expression group was significantly higher than that in the control group (P<0.05). The relative expression levels of PI3K and AKT in the low expression group were significantly higher than those in the control group, and the relative expression levels of PI3K and AKT in the high expression group were significantly lower than those in the control group (P<0.05). CONCLUSION: miR-106 b is highly expressed in breast cancer, and the higher the expression, the more sensitive breast cancer cells are to cisplatin chemotherapy.

Key words: miR-106 b, breast cancer, cisplatin, chemotherapy sensitivity

CLC Number:

R965.2

ZHENG Zhongqiu, XIE Bojian, CUI Binbin, KE Yichen, LIN Yi. miR-106 b expression in breast cancer tissues and mechanism of enhancing cisplatin sensitivity in breast cancer cells[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(5): 541-545.

References

［1］Li Q, Diao S, Li H, et al. Applying decision trees to establish risk rating model of breast cancer incidence based on non-genetic factors among Southwest China females［J］. Zhonghua Zhong Liu Za Zhi, 2018, 40(11): 872-877.
［2］Cassai A, Bonvicini D, Ruol M, et al. Erector spinae plane block combined with a novel technique for selective brachial plexus block in breast cancer surgery［J］. Korean J Anesthesiol, 2018, doi: 10.4097/kja.d.18.00266.
［3］Klaschik K, Hauke J, Neidhardt G, et al. The GPRC5A frameshift variant c.183del is not associated with increased breast cancer risk inBRCA1 mutation carriers ［J］. Int J Cancer, 2018, 144(7): 1761-1763.
［4］Santana Dos Santos E, Lallemand F, Burke L, et al. Non-coding variants in BRCA1 and BRCA2 genes: potential impact on breast and ovarian cancer predisposition［J］. Cancers (Basel), 2018, 10(11). pii: E453
［5］Wang L, Shang X, Feng Q. LncRNA TATDN1 contributes to the cisplatin resistance of non-small cell lung cancer through TATDN1/miR-451/TRIM66 axis［J］. Cancer Biol Ther, 2019, 20(3): 261-271.
［6］Cui Y, Qin L, Tian D, et al. ZEB1 promotes chemoresistance to cisplatin in ovarian cancer cells by suppressing SLC3A2［J］. Chemotherapy, 2018, 63(5): 262-271.
［7］Yen CS, Su ZR, Lee YP, et al. miR-106b promotes cancer progression in hepatitis B virus-associated hepatocellular carcinoma［J］. World J Gastroenterol, 2016, 22(22): 5183-5192.
［8］Weseslindtner L, Macheleidt I, Eischeid H, et al. Micro RNAs mir-106a, mir-122 and mir-197 are increased in severe acute viral hepatitis with coagulopathy［J］. Liver Int, 2016, 36(3): 353-360.
［9］Han EC, Park JW, Kwon YH, et al. Do the oncological and surgical outcomes of young and older women differ in the treatment of colorectal cancer［J］? J Womens Health (Larchmt), 2019, 28(2): 258-267.
［10］Yan CX, Huang PT, Shentu WH, et al. Value of double contrast-enhanced ultrasound QontraXt three-dimensional pseudocolor quantitative analysis to therapeutic effect evaluation of preoperative neoadjuvant chemotherapyin advanced gastric cancer patients［J］. Zhonghua Zhong Liu Za Zhi, 2018, 40(11): 857-863.
［11］Atkinson CJ, Kawamata F, Liu C, et al. EGFR and Prion protein promote signaling via FOXO3a-KLF5 resulting in clinical resistance to platinum agents in colorectal cancer［J］. Mol Oncol, 2019, 13(4): 725-737.
［12］王彩玲, 王俊生. 培美曲塞联合顺铂治疗乳腺癌无症状脑转移的临床研究［J］. 中国合理用药探索, 2017, 14(12): 7-9.
［13］Yi D, Xu L, Wang R, et al. miR-381 overcomes cisplatin resistance in breast cancer by targeting MDR1［J］. Cell Biol Int, 2019, 43(1): 12-21.
［14］Zhu W, Li J, Wu S, et al. Triptolide cooperates with cisplatin to induce apoptosis in gemcitabine-resistant pancreatic cancer［J］. Pancreas, 2012, 41(7): 1029-1038.
［15］ Fahim Golestaneh A, Lecker LSM, Schlegel J, et al. Large scale in-vivo micro-RNA loss of function screen identified miR-29a, miR-100 and miR-155 as modulators of radioresistance and tumor-stroma communication［J］. Int J Cancer, 2019, 144(11): 2774-2781.

[1]	HE Lihua, ZHU Xiuzhi, JIANG Yizhou. Research progress on immunotherapy for triple-negative breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 842-853.
[2]	ZHANG Huyunlong, ZHU Xiuzhi, JIN Xi, SHAO Zhimin. Mechanisms of endocrine-resistance and therapeutic breakthroughs in hormone receptor-positive, HER2-negative breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 854-865.
[3]	FU Xiaoyu, KONG Deguang, LI Juanjuan. Treatment progress of triple positive breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 866-875.
[4]	LUO Shiping, ZHANG Jie, YU Yushuai, SONG Chuangui. Advances in targeted therapy for HER2-positive breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 876-886.
[5]	XIANG Yimei, ZHANG Ningning, HUANG Yuxin, ZENG Xiaohua. Research progress of biomarkers related to the efficacy of HER2 positive breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 887-897.
[6]	CHEN Keyu, HUANG Yuan, WANG Xiaojia, ZHENG Yabing. Clinical application and research progress of antibody drugs conjugation in breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 898-909.
[7]	LI Mengxi, ZHANG Kejing, XIA Fan. Research progress in vaccine for breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 918-925.
[8]	WANG Zhi, ZHOU Xin, HE Xueru, FU Yuhao, XUN Xuejiao, LI Ying, DONG Zhanjun. Clinical research progress of palbociclib in treatment of breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 205-213.
[9]	WANG Xiu, JI Qilin, PEI Wenjun, ZENG Ying. 3-bromopyruvate cholesterol ester enhances the sensitivity of breast cancer cells to tamoxifen [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1093-1100.
[10]	WU Shuai, YANG Jun, ZHENG Yun. Dual role of miRNA in breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 814-821.
[11]	WANG Xinli, XU Xiaqing, FANG Hanbing, GUO Yuzhong. Study of TPA on enhancing the anti-tumor effects of cisplatin and reducing its renal toxicity [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(5): 535-543.
[12]	SHI Jingbin, XIONG Yang. Research progress on interaction between tumor microenvironment and breast cancer cells leading to tumor metastasis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(5): 562-574.
[13]	DONG Wei, HUANG Xiaoying, XIE Bingbin, TANG Xilan, LI Hongming, QIU Yumei, ZHAO Guowei, LIANG Xinli. Effects of oxypeucedanin on the resistance of breast cancer MCF-7/DOX cells to doxorubicin [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 260-266.
[14]	CUI Hua, YAN Hongxia, YIN Mei. Effects of down-regulating lncRNA LINC00176 on cisplatin resistance and autophagy in lung cancer A549/DDP cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 616-623.
[15]	LIU Yunfan, DU Yuemei, LIU Xiaoyi, GAO Liping. Effects of lycium barbarum polysaccharides on cis-dichlorodiamineplatinum (II)-induced apoptosis in mouse testis sertoli cells TM4#br# [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 624-630.